In addition, the defendants agreed to stop making pain-relief claims unless they are true and supported by reliable scientific evidence. They also agreed to stop misrepresenting clinical prop or the scope of FDA clearance for any device.
“Claiming pain relief without scientific support harms consumers”
In a statement, Consumer Protection Bureau Deputy Director Daniel Kaufman said, “With the opioid crisis, consumers are searching for drug-free pain relief. Devices claiming pain relief without scientific support harm consumers and undermine the market for non-drug products. The FTC will act on empty promises of pain relief.”
In a separate statement, FTC Commissioner Christina Wilson expressed that she concurs in part and dissent in part of the Commission’s decision approving the complaint and proposed consent order against the defendants.
According to Commissioner Wilson, she concurs with the FTC’s allegations against the defendants. However, she is questioning whether the Commission’s “evaluation in this matter crossed the line from ensuring the existence of reliable data for advertising claims to a quest for “Truth.”
